MUTYH-Associated Polyposis Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About MUTYH-Associated Polyposis
MYH-associated polyposis (MAP) is a hereditary condition characterized by an increased risk of developing multiple colorectal polyps and, subsequently, colorectal cancer. Managing this genetic predisposition often involves ongoing surveillance and potential treatments. TheDrugClub helps make necessary medications more accessible and affordable, easing the financial burden for individuals and families facing this diagnosis.
MYH-associated polyposis (MAP) is a genetic disorder that significantly increases an individual's lifetime risk of developing colorectal cancer. Unlike some other hereditary polyposis syndromes, MAP is inherited in an autosomal recessive pattern, meaning a person must inherit a mutated MUTYH gene from both parents to develop the condition. Those with MAP typically develop multiple adenomatous polyps (growths) in their colon and rectum, often starting in adulthood. While fewer polyps might be present compared to conditions like Familial Adenomatous Polyposis (FAP), the risk of these polyps turning cancerous is substantial.
Diagnosis usually involves genetic testing for the MUTYH gene mutation, often prompted by a family history of colorectal cancer or the presence of multiple polyps during a colonoscopy. Management primarily focuses on early detection and prevention. This includes regular, intensive colonoscopic surveillance to identify and remove polyps before they become cancerous. Depending on the number and nature of the polyps, surgical intervention, such as a colectomy (removal of part or all of the colon), may be recommended to reduce cancer risk. While the primary treatments are often procedural, individuals may require medications for pain management post-surgery, anti-inflammatory drugs, or specific treatments should colorectal cancer develop. Additionally, medications for related gastrointestinal issues or other health concerns are common.
For those managing MAP, the ongoing costs of care, including prescriptions, can add up. This is where
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.